Should you buy COMPASS Pathways stock now?
Yes, the technical signal for COMPASS Pathways is currently BUY. COMPASS Pathways trades at $13.49 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is negative (bearish trend) at -0.176 with rising momentum (signal: -0.254); RSI is at 61.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $23.75 points to 76.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for COMPASS Pathways stock?
The average analyst price target for COMPASS Pathways is $23.75. The current price is $13.49, which gives an upside of 76.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $21.38 and $26.13.
Is COMPASS Pathways a dividend stock?
No, COMPASS Pathways does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of COMPASS Pathways stock?
COMPASS Pathways is rated as a stock with extreme risk. the annual standard deviation is 89.6%, which classifies the stock as extreme risk.
Is COMPASS Pathways overvalued?
No, COMPASS Pathways is considered undervalued based on the analyst price target (76.1% upside). COMPASS Pathways has the following valuation ratios: a P/B ratio of 4.7. The analyst price target suggests that the stock is undervalued by 76.1%.
Is COMPASS Pathways overbought?
No, COMPASS Pathways is not overbought. RSI is at 61.6 (neutral zone). The technical indicators show: RSI is at 61.6 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 10.9% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next COMPASS Pathways earnings report?
The date of the next earnings report for COMPASS Pathways has not been published yet. Check the company's investor calendar for updates.
Is COMPASS Pathways shorted?
Yes, COMPASS Pathways is shorted with 9.6% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying COMPASS Pathways stock?
No, insiders are not buying COMPASS Pathways shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 17,328,775 $ sold. Active sellers include Nath Kabir, Loxam Teri, ATAI Life Sciences N.V. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is COMPASS Pathways a good stock?
Based on our total score, COMPASS Pathways is rated as a poor stock with a total score of 37 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 8/100, Quality: 11/100, Momentum: 93/100. In addition: analysts see 76.1% upside to the price target; technical signal: Buy. Whether COMPASS Pathways is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for COMPASS Pathways stock?
The outlook for COMPASS Pathways based on current data: the average analyst price target is $23.75 (+76.1%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is COMPASS Pathways stock rising?
COMPASS Pathways is rising right now. The technical indicators show: the price is 10.9% above the 20-day average; short interest is 9.6% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can COMPASS Pathways go?
The average analyst price target for COMPASS Pathways is $23.75, which corresponds to a potential gain of 76.1% from the current price of $13.49. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can COMPASS Pathways fall?
We lack enough history to give a specific floor for COMPASS Pathways. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does COMPASS Pathways do?
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and... The company belongs to the Sundhed sector, more specifically the Medicinsk behandling industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate COMPASS Pathways as an investment.
Did COMPASS Pathways raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from COMPASS Pathways. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is COMPASS Pathways making money or losing money?
We have no current profitability data for COMPASS Pathways. See the latest report in the earnings history above.
Can COMPASS Pathways go bankrupt?
The bankruptcy risk of COMPASS Pathways is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.64 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 38% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does COMPASS Pathways have a lot of debt?
No, COMPASS Pathways has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 38%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
